



# PHARMACY TECHNICIAN POCKET GUIDE: Tdap VACCINE

## Important facts about pertussis:

- Pertussis spreads easily from person to person through coughing and sneezing.<sup>1</sup> Persons with pertussis are most infectious through the third week after the coughing fits begin. Pertussis can be especially serious in young infants and can lead to death<sup>2</sup>
- Teens and adults with pertussis, especially those who did not get pertussis vaccines, may experience bursts of numerous and rapid coughs (paroxysms). The cough can cause complications, such as difficulty sleeping, weight loss, urinary incontinence, syncope, and broken ribs<sup>2,3</sup>

If the patients meet any of the criteria listed in the section below, refer them to the pharmacist to discuss Tdap vaccination.

## Who should be vaccinated?

General Recommendations from the Centers for Disease Control and Prevention (CDC)<sup>4,5</sup>:

- **Adolescents 11–18 years of age:** These persons should receive a single dose of Tdap, preferably at a preventive care visit at age 11–12 years. To ensure continued protection against tetanus and diphtheria, 1 booster dose of either Td or Tdap should be administered every 10 years throughout life
- **Adults 19 years of age and older:** Regardless of the interval since their last tetanus or diphtheria toxoid-containing vaccine, persons aged  $\geq 19$  years who have never received a dose of Tdap should receive 1 dose of Tdap. Booster doses of either Td or Tdap should be administered every 10 years throughout life
- **Pregnant women:** Should receive 1 dose of Tdap during each pregnancy. Tdap should be administered at 27–36 weeks' gestation, preferably during the earlier part of this period, although it may be administered at any time during pregnancy
- **Wound management:** Appropriate persons aged  $\geq 11$  years whose previous tetanus toxoid-containing vaccine was  $>5$  years. Tdap is preferred for persons who have not previously received Tdap or whose Tdap history is unknown. For a pregnant woman, Tdap should be used. For nonpregnant persons with documentation of previous Tdap vaccination, either Td or Tdap may be used

# PHARMACY TECHNICIAN POCKET GUIDE: Tdap VACCINE

## Who should not be vaccinated?

- Patients who have had a life-threatening allergic reaction (eg, anaphylaxis) to a dose of Tdap or to any diphtheria toxoid, tetanus toxoid, or pertussis-containing vaccine, or have a severe allergy to any component of this vaccine<sup>5</sup>
- Patients who developed encephalopathy (eg, coma, decreased level of consciousness, prolonged seizures) not attributable to another identifiable cause within 7 days of administration of a previous dose of DTP, DTaP, or Tdap<sup>4,5</sup>

Precautions should be considered when consulting with patients who<sup>5</sup>:

- Have a moderate or severe acute illness with or without fever
- Had Guillain-Barré syndrome within 6 weeks after a previous dose of a tetanus toxoid-containing vaccine
- Have a history of Arthus-type hypersensitivity reactions after a previous dose of a tetanus- or diphtheria toxoid-containing vaccine; defer vaccination until at least 10 years have elapsed since the last tetanus toxoid-containing vaccine
- Have a progressive or unstable neurological disorder, uncontrolled seizures, or progressive encephalopathy; defer vaccination until treatment is initiated and the condition has stabilized

Tdap = tetanus, diphtheria, and acellular pertussis;  
Td = tetanus and diphtheria

### References:

1. Pertussis: causes and how it spreads. Centers for Disease Control and Prevention. Reviewed: August 4, 2022. Accessed June 16, 2023. <https://www.cdc.gov/pertussis/about/causes-transmission.html>.
2. Pertussis. Centers for Disease Control and Prevention. Reviewed: October 19, 2022. Accessed June 16, 2023. <https://www.cdc.gov/vaccines/pubs/pinkbook/pert.html>.
3. Pertussis: clinical complications. Centers for Disease Control and Prevention. Reviewed August 4, 2022. Accessed June 30, 2023. <https://www.cdc.gov/pertussis/clinical/complications.html>.
4. Use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccines: updated recommendations of the Advisory Committee on Immunization Practices — United States, 2019. Reviewed January 23, 2020. Accessed June 30, 2023. <https://www.cdc.gov/mmwr/volumes/69/wr/mm6903a5.html>.
5. Vaccines and preventable diseases: diphtheria, tetanus, and pertussis vaccine recommendations. Centers for Disease Control and Prevention. Reviewed March 10, 2023. Accessed June 16, 2023. <https://www.cdc.gov/vaccines/vpd/dtap-tdap-td/hcp/recommendations.html>.

Trademarks are owned by or licensed to the GSK group of companies.



©2023 GSK or licensor.  
PTULBND230002 July 2023  
Produced in USA. 0002-0025-43